Introduction
============

In the United States, the age-standardized cancer death rate began declining in the early 1990s, largely because of declines in deaths from lung and prostate cancer in men, breast cancer in women, and colorectal cancer in both sexes ([@R1]). The age-standardized death rate approximates the population's risk of dying from cancer and is used to compare risk of death between populations or over time within a population. A decline in the death rate means that the overall risk of dying from cancer in the population has decreased. However, age-standardized rates do not convey the full extent of the cancer burden, as they effectively remove the influence of demographic changes in the population. During this time, the observed number of cancer deaths has continued to increase ([@R2]).

The number of cancer deaths is a function of the population's risk of dying from cancer and the population's age structure and size. The observed increase in the number of cancer deaths reflects the increased risk of dying from cancer with age, and during the past several decades, the US population has grown, particularly in the older age groups ([@R3]). These demographic trends and increasing cancer burden are forecast to continue as the cohort born following World War II enters the age groups most at risk of dying from cancer ([@R4]).

In 1971, the US Congress passed the National Cancer Act, which signaled a national effort against cancer ([@R5]) and led to the establishment of the Surveillance, Epidemiology, and End Results (SEER) Program in 5 states and 4 metropolitan areas ([@R1]). Since then, cancer registries ([@R2]) and cancer control programs ([@R6]) have been established in all states. More recently, the US Department of Health and Human Services (HHS) issued Healthy People 2020 (HP2020) ([@R7]), which included several objectives for reducing cancer mortality. Each objective has a baseline measure and a target to be achieved by 2020. Most of the cancer mortality objectives include a 10% reduction in the age-standardized death rate from 2007 (baseline) to 2020. The colorectal cancer target calls for a 15% reduction in death rates.

Trends in population risk, size, and age structure have been used to predict the future of cancer mortality in other countries ([@R8]). To determine whether HP2020 cancer mortality targets are likely to be met, we used mortality data and population estimates and projections to assess the contribution of changes in population risk, growth, and aging on cancer deaths from 1975 to 2020 for all cancer sites and the top 23 cancers by sex and race.

Methods
=======

Mortality data were from the Centers for Disease Control and Prevention (CDC)'s National Vital Statistics System ([@R9]). Cause of death information was coded based on the *International Classification of Diseases* (*ICD*) versions in use at the time of death, and cause of death recodes were applied to accommodate consistency over time ([@R2]). For these analyses, we selected malignant neoplasms (C00--97). We used population estimates for 1975 through 2009 available from the SEER Program and obtained population projections for 2010 through 2020 from the US Census Bureau's Population Projections Program ([@R10]).

To estimate the relative contribution to changes in the total number of new cancer deaths each year that can be attributed to changes in population risk (including changes in diagnosis and treatment practices) and demographic changes related to population size and age structure, we generated 3 sets of data by sex and race (white and black) for each year (1976--2009) based on a method first published in the 1999 Canadian Cancer Statistics report ([@R11]). The dotted line in [Figure 1](#F1){ref-type="fig"} represents the number of deaths from cancer that occurred in 1975. The lowest solid line represents the number of cancer deaths that would have occurred each year if the population size and age structure had remained the same as they were in 1975. This line is similar to the age-standardized death rate and reflects the impact of changes in population risk including changes in diagnosis and treatment practices. The middle line represents the number of deaths that would have occurred if the age structure of the population had remained the same as it was in 1975. This line reflects the impact of changes in risk and population growth. The top line represents the number of deaths that actually occurred and thus reflects the combined impact of changes in population risk, growth, and aging. The yearly difference between each set of death counts denotes the relative contribution to the overall change in the number of deaths since 1975 attributable to population risk, growth, and aging, respectively. A decline in risk during this time results in negative death counts as fewer deaths are attributed to risk compared with the baseline year.

![Trends in deaths from all cancers combined attributed to population risk (including diagnostic and treatment practices), growth, and aging (1975--2009), by sex and race (white, black).\
Year of Diagnosis1975 Cancer DeathsPopulation AgingPopulation GrowthPopulation Risk1975 Cancer Deaths in White Males1975175,299175,299175,299175,2991976175,299180,269178,746177,3521977175,299184,261180,914178,0521978175,299189,013183,867179,4111979175,299193,447186,412180,2531980175,299198,189188,928181,2931981175,299199,373188,719179,7331982175,299204,473191,831181,3871983175,299208,060193,615181,7511984175,299211,373195,255182,0561985175,299215,088197,098182,5021986175,299218,383198,756182,6691987175,299221,766200,276182,7771988175,299224,520201,280182,3931989175,299228,317202,921182,5171990175,299232,617205,291182,9011991175,299236,430206,933182,2831992175,299238,504206,996180,1761993175,299241,940208,120179,1681994175,299243,012207,603176,8871995175,299244,026206,278173,9721996175,299243,970204,708170,9581997175,299243,212202,090167,0471998175,299244,124200,983164,4621999175,299247,392201,753163,4762000175,299247,396200,120160,6682001175,299248,142199,105158,3972002175,299249,864198,171156,3492003175,299249,045191,520152,6272004175,299247,446191,700148,8682005175,299250,475191,520147,5292006175,299250,318189,252144,5482007175,299252,047184,752141,9432008175,299254,119186,712140,1842009175,299255,040184,752137,6861975 Cancer Deaths in White Females1975148,711148,711148,711148,7111976148,711153,688152,569151,3771977148,711157,052153,985151,4781978148,711161,273156,378152,4311979148,711163,890157,147151,7601980148,711169,970160,982154,1971981148,711173,307162,654154,6701982148,711178,167165,506156,2851983148,711181,950167,359156,9961984148,711187,266170,715159,1711985148,711190,649172,523159,8601986148,711193,967174,107160,3011987148,711196,727175,124160,2501988148,711200,633177,296161,2421989148,711205,867180,475163,0991990148,711208,986181,889163,0261991148,711213,108184,329163,5621992148,711216,036185,438162,8931993148,711219,997187,521163,1161994148,711222,817189,061162,9631995148,711224,905189,505161,9271996148,711225,471189,125160,2311997148,711225,336187,794157,7031998148,711226,051187,187155,8541999148,711229,839189,280156,3122000148,711232,608190,664156,2692001148,711231,505188,998153,7592002148,711232,613188,708152,4452003148,711232,500187,329150,3072004148,711230,682184,914147,3802005148,711231,652184,070145,7222006148,711232,251183,502144,2532007148,711231,888181,551141,6492008148,711231,767179,705139,2412009148,711231,947178,483137,4271975 Cancer Deaths in Black Males197521,88421,88421,88421,884197621,88422,74822,67322,358197721,88423,61623,44822,829197821,88424,24923,98723,055197921,88424,82724,49023,196198021,88425,85525,75023,725198121,88426,47026,40524,004198221,88427,21727,12724,330198321,88427,92727,80324,613198421,88428,84828,73925,128198521,88429,02228,96425,005198621,88429,36029,34324,994198721,88429,92129,92725,157198821,88430,31930,37925,196198921,88431,45031,58225,825199021,88431,99332,26125,937199121,88432,08932,38625,498199221,88432,15632,53825,035199321,88433,06933,42325,188199421,88432,85833,20524,548199521,88432,87833,10124,037199621,88432,97333,06623,608199721,88432,71732,60722,876199821,88432,52132,16422,181199921,88432,84932,28621,892200021,88432,81531,90621,292200121,88432,67631,60320,808200221,88432,62531,27220,341200321,88432,44230,57519,682200421,88432,44130,29919,252200521,88432,72430,09418,881200621,88432,55529,54118,284200721,88433,06729,56418,041200821,88433,01829,03117,477200921,88433,44128,96817,2181975 Cancer Deaths in Black Females197515,74715,74715,74715,747197615,74716,40816,28516,034197715,74717,19716,89716,385197815,74717,55917,07516,307197915,74718,14717,49916,440198015,74719,17318,50416,940198115,74719,34618,55216,756198215,74720,08619,11817,030198315,74720,80319,64817,277198415,74721,40720,09517,455198515,74721,87420,38117,484198615,74722,61020,95517,750198715,74723,09321,28617,797198815,74723,64421,63417,845198915,74724,11421,98517,885199015,74725,08222,82418,271199115,74725,82623,35618,316199215,74726,24523,78318,269199315,74726,79624,15418,189199415,74727,07724,32617,979199515,74727,72324,80618,021199615,74727,79324,69517,649199715,74728,61625,22317,729199815,74728,67225,12417,377199915,74729,10125,31917,243200015,74729,12725,04916,819200115,74729,49025,19816,720200215,74729,98925,33016,622200315,74730,21825,16316,344200415,74730,05624,84615,966200515,74730,43724,71615,708200615,74730,52624,53015,411200715,74730,97824,64115,288200815,74730,93424,30914,862200915,74731,20424,19514,624](PCD-12-E104s01){#F1}

To project age-standardized death rates and counts for 2010--2020, we used Nordpred software ([@R12]), which uses an age-period-cohort regression model with data aggregated into six 5-year calendar periods (1980--2009) and fifteen 5-year age groups (15--19, ..., 80--84, ≥85). We fit a separate model for each of the current top 23 cancer causes of death and all other cancer deaths combined by sex and race (all, white, and black): R*~ap~* = (A~a~ + D × p + P~p~ + C~c~)^5^where *R~ap~* is the death rate in age group a in calendar period p, A~a~ is the age component for age group a, D is the drift parameter (the common linear effect of both calendar period and birth cohort), P~p~ is the nonlinear period component of period p, and C~c~ is the nonlinear cohort component of cohort. To offset exponential increases or decreases in death rates, the models used the Power-5 link function. Assuming that trends are not likely to continue indefinitely, we reduced the drift component D by 25% and 50% in the second and third 5-year periods, respectively. Both these modifications have been shown empirically to improve predictions. Nordpred uses a goodness-of-fit test to determine the optimum number of calendar periods (4--6 candidate periods are sufficient) to include in the model ([@R12]). Significant curvature over time was determined by comparing a model with and without a second order term for calendar period (p), using a χ^2^ test for the difference in residual sum of squares between the models. If there was significant curvature, the slope from the last 10 years was projected; if not, the average linear trend (D) was used. Visual data inspection determined the starting age for each cancer site by sex and race such that each age group contained no fewer than 10 deaths. We calculated age-standardized death rates (per 100,000) using the US 2000 standard population weights ([@R13]). Predicted death counts were obtained by applying predicted age-specific death rates to the 2010 through 2020 population projections. We apportioned cancer death counts by changes in population risk and in demographics (population size and age structure combined) ([@R14]). We considered a change of 10% or more in age-adjusted rates or death counts as an increase or decrease; otherwise, we considered rates and death counts to be stable.

Results
=======

From 1975 through 2009, the number of cancer deaths increased 45.5% among white males, 56.0% among white females, 52.8% among black males, and 98.2% among black females ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). For each sex and race group, the number of cancer deaths attributed to risk decreased, whereas the number of cancer deaths attributed to population growth and aging increased as follows: white males (−21.5% risk, 26.8% growth, 40.1% aging); white females (−7.6% risk, 27.6% growth, 36.0% aging); black males (−21.3% risk, 53.7% growth, 20.4% aging); and black females (−7.1% risk, 60.8% growth, 44.5% aging) ([Table 1](#T1){ref-type="table"}).

###### Observed Cancer Deaths (All Sites Combined) and Percentage Change From Population Risk, Growth, and Aging by Sex and Race, 1975--2009

  Death Year             Male      Female                                                   
  ---------------------- --------- --------- -------- -------- --------- --------- -------- --------
  **White**                                                                                 
  1975                   175,299   NA        NA       NA       148,711   NA        NA       NA
  1980                   198,189   5,994     7,635    9,261    169,970   5,486     6,781    8,993
  1990                   232,617   7,602     22,391   27,325   208,986   14,315    18,864   27,096
  2000                   247,396   −14,631   39,464   47,265   232,608   7,558     34,396   41,943
  2009                   255,040   −37,613   47,063   70,292   231,947   −11,284   41,053   53,467
  \% Change 1975--2009   45.5      −21.5     26.8     40.1     56.0      −7.6      27.6     36.0
  **Black**                                                                                 
  1975                   21,884    NA        NA       NA       15,747    NA        NA       NA
  1980                   25,855    1,841     2,024    106      19,173    1,193     1,562    671
  1990                   31,993    4,053     6,325    −269     25,082    2,524     4,554    2,258
  2000                   32,815    −592      10,615   908      29,127    1,072     8,228    4,080
  2009                   33,441    −4,666    11,749   4,474    31,204    −1,123    9,573    7,007
  \% Change 1975--2009   52.8      −21.3     53.7     20.4     98.2      −7.1      60.8     44.5

Abbreviations: NA, not applicable.

[Figure 2](#F2){ref-type="fig"} shows 1975 through 2009 (observed) and 2010 through 2020 (predicted) age-standardized cancer death rates for all sites combined and for the 7 site-specific cancers included in the cancer mortality objectives for Healthy People 2020. (Additional information can be found at <http://www.cdc.gov/cancer/dcpc/research/articles/cancer_2020_figures.htm>.) [Table 2](#T2){ref-type="table"} shows predicted 2020 deaths by race (all races combined, white, black), sex, and cancer site, with the percentage change in deaths from 2007 (baseline) and 2020 apportioned because of changes in risk and demographics (population growth and aging combined). By 2020, we predict cancer deaths to increase 15.2% among men (−23.0% attributable to risk, 38.2% attributable to demographics) and begin to stabilize (8.1%) among women (−19.5% attributable to risk, 27.6% attributable to demographics). Results varied by cancer site, sex, and race. We predict that cancer risk will decrease for 13 of 19 cancers among men and 15 of 21 cancers in women, while the number of deaths will increase for 11 of 19 cancer sites among men and 9 of 21 cancer sites among women, in large part because of the demographic component. We predict that risk of death will increase for cancers of the corpus and uterus among black women, liver and intrahepatic bile duct among both men and women (both races), and for thyroid cancer in women (both races). We predict that the number of deaths for colorectal cancer and non-Hodgkin's lymphoma will decrease among white women, for esophageal cancer among black men and women, Hodgkin's lymphoma among white men and women, laryngeal cancer among black men, and cancers of the oral cavity and pharynx among black women.

![Trends in observed and predicted age-adjusted death rates for all sites combined and for the 7 site-specific cancers included in the Healthy People 2020 cancer mortality objectives by sex and race, 1975--2020.\
YearWhite MaleWhite FemaleBlack MaleBlack FemaleAll Cancer Sites Combined1975254.00158.99320.45174.181976257.50161.69328.45179.101977258.78161.61337.95181.601978261.64162.54340.91181.531979263.24161.69344.67182.731980265.02164.17353.91189.241981263.26164.55358.65187.471982266.28166.11364.86190.171983267.22166.69369.32193.241984267.55169.02377.93195.671985268.24169.58377.82196.311986268.83170.01378.92199.051987268.96169.87383.24199.911988269.46170.94384.17200.361989270.25172.88395.28200.871990271.48172.89399.14205.381991271.19173.41395.85207.391992268.91172.58389.20205.801993267.89172.82394.76206.291994264.73172.62385.20204.061995261.46171.73379.02204.531996256.83169.85373.70200.941997251.58167.35363.18202.531998247.62165.38353.13198.381999247.14165.92349.23197.542000243.31165.94341.48193.262001240.03163.52334.93192.182002237.25162.14327.14191.512003231.79159.81316.59188.812004226.30156.68309.94183.642005224.75155.18303.63181.132006219.98153.59293.91177.572007216.61150.84291.00175.782008213.29148.23280.09170.952009209.78146.46274.73168.172010206.52144.69268.96166.512011203.12142.66262.53163.832012199.72140.63256.09161.142013197.16138.94251.54158.882014194.59137.24246.99156.632015192.02135.54242.45154.372017186.88132.15233.35149.852018185.20130.87230.68148.282019183.53129.58228.00146.712020181.85128.30225.33145.15Cervix Uteri1975---4.75---13.351976---4.68---12.861977---4.22---12.191978---4.15---11.641979---3.95---10.611980---3.77---10.781981---3.74---9.891982---3.51---9.771983---3.43---9.761984---3.36---9.271985---3.27---8.981986---3.22---9.231987---3.13---8.221988---3.10---8.151989---3.05---8.601990---3.19---7.771991---3.01---7.651992---3.01---8.071993---2.95---7.691994---3.00---6.711995---2.82---6.981996---2.87---6.201997---2.76---6.471998---2.65---5.911999---2.57---5.412000---2.47---5.432001---2.43---4.832002---2.28---4.982003---2.23---4.662004---2.18---4.522005---2.21---4.382006---2.21---4.342007---2.20---4.332008---2.17---4.192009---2.07---4.192010---2.09---4.012011---2.06---3.912012---2.03---3.822013---2.01---3.772014---2.00---3.722015---1.98---3.672016---1.96---3.622017---1.95---3.572018---1.94---3.552019---1.94---3.542020---1.93---3.53Colon and Rectum197533.2425.0630.0924.55197633.7625.4531.1626.26197733.4924.9731.4424.93197834.1225.1731.2025.66197933.9224.5731.5725.96198033.9924.3233.1825.89198133.1623.8532.8326.32198233.1123.4233.7126.12198333.3223.1132.9025.82198433.1223.4934.6526.22198532.7422.7734.1028.04198632.0122.0735.3626.35198731.8521.6335.1026.48198831.0421.1634.2925.88198930.5220.8236.3726.07199030.4320.1837.6426.59199129.3519.8535.8026.50199228.9919.4236.2325.43199328.1819.2835.8426.04199427.8918.8435.6624.88199527.1618.6436.3025.47199626.2917.9834.5224.86199725.6817.5935.0724.80199825.1317.4833.9024.78199924.9917.2034.5024.70200024.4517.0135.0123.89200123.8016.4833.4724.25200223.3416.0633.8622.95200322.5715.5132.7122.91200421.2314.7230.8721.41200520.5614.1331.2121.42200620.0214.1231.6520.29200719.6413.7329.7619.88200818.9813.3629.2818.97200918.5912.6827.5718.59201018.0012.5328.4818.33201117.4912.1728.0317.84201216.9911.8227.5717.36201316.6711.6027.2617.03201416.3611.3726.9516.70201516.0511.1526.6416.38201615.7410.9326.3216.05201715.4310.7126.0115.73201815.3110.6025.8915.57201915.1810.5025.7715.42202015.0610.4025.6515.27Female Breast1975---31.79---29.491976---32.17---30.471977---32.67---32.801978---31.90---32.141979---31.48---30.821980---31.93---31.681981---32.12---32.551982---32.31---33.751983---32.20---33.531984---32.90---35.941985---33.11---34.851986---32.93---35.441987---32.57---36.731988---33.09---37.781989---33.23---36.611990---33.02---38.001991---32.45---38.281992---31.43---37.091993---31.09---38.041994---30.56---37.741995---30.09---38.181996---29.05---37.131997---27.62---37.431998---27.01---35.531999---25.98---35.212000---26.17---34.382001---25.40---34.562002---24.97---34.202003---24.58---34.192004---23.85---32.422005---23.39---32.992006---22.92---31.802007---22.28---31.582008---21.85---31.222009---21.65---30.492010---21.01---30.222011---20.55---29.772012---20.08---29.312013---19.74---28.962014---19.40---28.602015---19.06---28.252016---18.72---27.892017---18.38---27.542018---18.16---27.302019---17.94---27.062020---17.73---26.82Lung and Bronchus197575.4717.6791.0117.34197677.5519.1093.9618.51197779.0920.09100.8019.91197880.7621.58101.6520.66197981.6422.42102.8922.24198083.2724.22106.6724.58198183.5225.10109.7125.10198285.1826.72112.5526.30198385.4028.28112.7628.73198486.2429.27117.9827.98198586.6930.81117.5029.64198687.0331.76119.1831.00198788.0933.04121.7732.48198887.8634.57122.1533.54198987.5736.27124.7234.87199088.4037.31125.1736.48199187.7638.12123.5837.16199285.9839.21121.0638.55199385.5239.97121.9837.72199483.7840.30118.6338.61199582.6240.97116.0838.84199681.1541.22113.1839.08199779.8341.52110.2140.53199878.4741.69107.4040.67199975.6740.86103.6140.00200075.4142.08100.9639.66200174.3342.0299.5838.81200272.8842.5996.0440.22200371.3442.2293.5940.25200469.8141.8991.2539.95200569.2241.5988.0440.15200667.2341.2485.0939.09200764.9741.1583.5838.16200863.7540.2379.6436.93200961.7739.8477.2235.99201060.8139.4474.8736.52201159.3138.9972.3136.02201257.8138.5469.7535.52201356.5738.0067.7934.95201455.3437.4665.8334.38201554.1136.9163.8733.81201652.8836.3761.9233.24201751.6535.8359.9632.67201850.7535.2858.6232.16201949.8634.7357.2931.65202048.9634.1855.9531.13Melanoma19752.881.740.560.4419763.101.940.740.3919773.171.930.690.4119783.321.900.610.4619793.462.020.640.4719803.411.900.550.5619813.452.070.560.5719823.641.990.560.4919833.632.040.630.4019843.792.030.450.5419853.822.060.580.4919863.922.090.700.3119874.132.020.570.5419884.072.130.530.4019894.152.100.570.5319904.212.200.650.4519914.312.020.650.5419924.272.060.570.4419934.312.060.420.5919944.262.030.440.4319954.352.020.510.4219964.502.140.510.3819974.412.050.490.5819984.591.980.450.5419994.271.980.520.3320004.282.030.600.5020014.381.990.350.4520024.251.960.500.3220034.391.970.440.4520044.481.940.570.3920054.542.060.490.4120064.631.970.630.3520074.531.920.540.4520084.611.890.460.3520094.772.050.550.3620104.581.940.510.3720114.571.920.510.3720124.561.910.500.3620134.531.890.500.3620144.501.880.500.3520154.471.860.490.3520164.441.850.490.3520174.411.830.490.3420184.371.810.480.3420194.321.790.480.3420204.271.780.480.34Oral Cavity and Pharynx19756.642.299.932.5219766.552.1710.552.6219776.672.2510.872.6519786.412.2110.692.6819796.252.3211.472.9719806.122.2212.482.7619815.962.1711.362.8419825.962.1311.462.9419835.732.1011.832.7619845.642.1211.702.3819855.442.0511.032.6219865.272.0711.352.9319875.012.009.952.5419885.141.9810.672.5519894.842.0010.442.5919905.071.9611.052.5219914.871.9510.062.7019924.661.899.972.3119934.681.8310.092.4419944.411.779.262.3919954.421.759.282.5419964.241.718.692.0719974.171.708.102.1919984.201.687.912.0919993.801.547.492.1220003.721.557.311.7620013.871.526.691.8120023.871.506.331.7320033.801.456.951.6520043.721.466.951.6320053.601.436.541.3820063.611.375.701.5020073.711.395.761.6020083.621.375.211.4720093.541.315.151.2320103.511.325.041.2920113.471.284.841.2420123.441.274.641.1920133.421.254.501.1520143.401.244.361.1120153.381.234.231.0720163.361.214.091.0320173.351.213.951.0020183.341.203.870.9720193.331.193.800.9420203.331.283.720.91Prostate197529.06---55.52---197629.93---55.60---197729.90---56.44---197830.62---58.49---197930.77---59.24---198030.77---61.99---198130.76---63.61---198231.09---62.36198331.57---64.55---198431.58---65.93---198531.28---67.26---198632.46---67.39---198732.57---68.88---198833.38---69.57---198934.54---71.71---199035.67---77.98---199136.50---78.24---199236.29---79.84---199336.26---81.86---199435.64---79.96---199534.41---78.20---199633.00---78.84---199731.35---74.30---199829.89---72.77---199928.91---70.13---200027.75---68.93---200126.87---67.86---200226.20---65.04---200324.85---60.48---200423.86---59.20---200523.15---57.29---200622.17---54.01---200722.05---55.27---200821.17---49.49---200920.22---50.00---201019.86---47.69---201119.24---45.89---201218.62---44.09---201318.27---43.02---201417.92---41.95---201517.57---40.88---201617.22---39.81---201716.86---38.74---201816.74---38.35---201916.61---37.95---202016.49---37.55---[^1]](PCD-12-E104s02){#F2}

###### Predicted (2020) Deaths and Percentage Change From 2007 to 2020 by Risk and Demographics (Population Growth and Aging Combined) for All Cancer Sites Combined and for the Top 23 Cancers by Race and Sex

  Cancer Site                 All Races   White   Black                                                                    
  --------------------------- ----------- ------- ------- ------ --------- ------- ------- ------ -------- ------- ------- ------
  **Males**                                                                                                                
  All cancer sites combined   337,280     15.2    −23.0   38.2   285,800   13.4    −21.4   34.8   38,248   15.7    −32.7   48.3
  Brain and other CNS         8,752       19.6    −11.5   31.1   7,920     17.2    −10.0   27.2   530      31.2    −9.1    40.3
  Colon and rectum            29,244      8.3     −29.0   37.3   23,568    3.3     −30.7   33.9   4,375    27.9    −19.5   47.4
  Esophagus                   14,313      33.1    −4.9    38.0   13,010    37.1    2.9     34.1   899      −14.8   −65.3   50.6
  Hodgkin lymphoma            680         −3.7    −29.5   25.8   553       −11.0   −33.9   22.9   72       −2.5    −32.1   29.6
  Kidney and renal pelvis     9,788       22.9    −14.4   37.3   7,932     13.4    −20.4   33.7   1,032    38.7    −7.3    46.0
  Larynx                      3,047       5.4     −31.9   37.3   2,512     10.0    −23.6   33.7   468      −14.5   −63.6   49.1
  Leukemia                    15,006      20.7    −15.5   36.2   13,278    18.7    −14.4   33.1   1,224    27.9    −14.7   42.6
  Liver and IBD               20,757      83.0    49.8    33.2   16,216    82.5    52.8    29.7   2,983    87.4    42.8    44.6
  Lung and bronchus           91,592      3.7     −37.1   40.8   78,588    2.8     −34.4   37.2   9,817    −0.2    −51.6   51.4
  Melanoma                    6,728       22.2    −11.4   33.6   6,546     21.0    −8.6    29.6   81       36.7    −4.5    41.2
  Myeloma                     6,831       17.6    −22.0   39.5   5,403     12.8    −23.6   36.4   1,157    32.5    −16.1   48.7
  Non-Hodgkin lymphoma        10,662      −3.1    −39.9   36.8   9,369     −5.8    −39.5   33.7   893      19.2    −23.9   43.1
  Oral cavity and pharynx     6,216       12.8    −22.4   35.2   5,389     18.3    −13.4   31.7   698      −9.2    −55.8   46.6
  Pancreas                    24,339      42.1    3.6     38.4   20,674    39.9    5.1     34.8   2,541    34.2    −14.3   48.6
  Prostate                    30,914      6.3     −33.9   40.2   24,778    4.7     −32.4   37.1   5,285    7.7     −41.6   49.3
  Stomach                     6,857       1.5     −35.3   36.8   4,951     −2.9    −36.4   33.5   1,264    6.0     −40.5   46.5
  Testis                      356         9.1     −3.4    12.4   315       6.9     −1.5    8.3    ---      ---     ---     ---
  Thyroid                     967         39.3    1.0     38.3   841       39.2    4.8     34.4   ---      ---     ---     ---
  Urinary bladder             13,113      36.0    −3.3    39.3   11,946    33.5    −2.8    36.2   887      56.9    8.9     48.0
  **Females**                                                                                                              
  All cancer sites combined   291,923     8.1     −19.5   27.6   242,196   4.4     −18.4   22.8   36,392   17.5    −24.9   42.3
  Brain and other CNS         6,771       14.4    −12.0   26.4   6,050     11.7    −10.1   21.7   438      13.2    −24.1   37.3
  Cervix uteri                4,085       1.6     −17.7   19.3   3,032     −0.2    −14.3   14.1   856      6.3     −26.5   32.8
  Colon and rectum            24,887      −5.1    −30.2   25.1   19,834    −10.0   −30.1   20.2   3,802    10.1    −32.9   42.9
  Corpus and uterus, NOS      10,407      39.6    8.7     30.9   7,847     31.6    6.7     25.0   2,092    61.6    10.6    50.9
  Esophagus                   3,004       5.7     −23.7   29.4   2,672     12.1    −12.5   24.6   339      −14.9   −58.7   43.9
  Female breast               40,434      −0.4    −25.5   25.0   32,065    −5.3    −25.8   20.6   6,683    15.3    −21.6   36.9
  Hodgkin lymphoma            490         −13.2   −35.3   22.0   424       −15.3   −33.1   17.8   55       −2.5    −33.6   31.1
  Kidney and renal pelvis     5,136       8.4     −19.5   27.9   4,382     5.7     −17.6   23.3   516      8.0     −33.6   41.6
  Larynx                      863         15.9    −16.0   31.9   747       20.1    −6.1    26.2   118      5.8     −44.1   49.9
  Leukemia                    10,180      7.2     −17.6   24.8   8,825     5.3     −14.9   20.2   923      3.7     −36.2   39.9
  Liver and IBD               8,576       47.8    20.7    27.1   6,853     44.9    22.5    22.4   1,046    55.6    13.8    41.8
  Lung and bronchus           76,679      9.0     −22.7   31.7   65,793    5.8     −21.1   26.8   7,926    19.2    −26.6   45.7
  Melanoma                    3,361       13.7    −9.5    23.2   3,195     12.1    −6.1    18.2   82       6.3     −34.3   40.5
  Myeloma                     4,811       −5.0    −34.0   29.1   3,611     −8.7    −32.6   24.0   947      −5.0    −51.4   46.3
  Non-Hodgkin lymphoma        7,831       −17.8   −43.2   25.5   6,813     −21.1   −42.1   20.9   641      0.0     −39.9   39.8
  Oral cavity and pharynx     2,615       2.3     −23.5   25.8   2,230     3.0     −18.5   21.5   232      −20.9   −61.0   40.1
  Ovary                       16,432      12.4    −16.3   28.7   14,122    7.9     −15.9   23.7   1,398    20.5    −24.0   44.5
  Pancreas                    23,117      36.1    7.9     28.2   18,999    32.7    9.4     23.3   2,981    37.0    −7.9    44.9
  Stomach                     4,460       −3.7    −27.8   24.1   3,159     −8.5    −27.4   18.9   822      2.1     −39.5   41.5
  Thyroid                     1,297       49.4    21.2    28.2   1,006     41.5    18.8    22.7   172      82.5    34.9    47.7
  Urinary bladder             4,961       18.1    −6.1    24.2   4,289     16.9    −3.0    19.9   544      16.1    −25.0   41.1

Abbreviations: ---, Data not shown because numbers were too small for analysis; Dem, demographics.

[Table 3](#T3){ref-type="table"} shows observed (2007), predicted (2020), and HP2020 target age-standardized death rates per 100,000 population, percent change from 2007 to 2020, and the year in which we predict death rates to meet HP2020 targets by cancer site. We predict declining death rates from 2007 to 2020 for the following cancers: all sites combined (15.6%), lung and bronchus (21.3%), female breast (19.6%), cervix uteri (12.5%), colon and rectum (22.5%), oral cavity and pharynx (16.0%), prostate (26.4%), and melanoma of the skin (7.4%). The years in which we project the age-standardized death rate to meet the HP2020 target rates are 2010 (prostate), 2011 (cervix uteri, oral cavity and pharynx), 2012 (female breast), 2013 (lung and bronchus, colon and rectum), and 2015 (all sites combined). We do not predict that melanoma age-standardized death rates will meet the goal of a 10% reduction by 2020.

###### Observed (2007) and Predicted (2020) Age-Standardized Death Rates (ASDR) per 100,000 Population and Overall Percentage Change for All Cancer Sites Combined and for the 7 Site-Specific Cancers Included in the Healthy People 2020 Cancer Mortality Objectives

  HP2020 Objectives/Cancer Site    2007 Observed ASDR   2020 Predicted ASDR   Percentage Change (2007--2020) ASDR   HP2020 Target ASDR   Year Predicted to Meet HP2020 Target
  -------------------------------- -------------------- --------------------- ------------------------------------- -------------------- --------------------------------------
  C-1, All cancer sites combined   179.3                151.4                 −15.6                                 161.4                2015
  C-2, lung and bronchus           50.7                 39.8                  −21.3                                 45.5                 2013
  C-3, female breast               23.0                 18.5                  −19.6                                 20.7                 2012
  C-4, cervix uteri                2.4                  2.1                   −12.5                                 2.2                  2011
  C-5, colon and rectum            16.9                 13.1                  −22.5                                 14.5                 2013
  C-6, oral cavity and pharynx     2.5                  2.1                   −16.0                                 2.3                  2011
  C-7, prostate                    24.2                 17.8                  −26.4                                 21.8                 2010
  C-8, melanoma                    2.7                  2.5                   −7.4                                  2.4                  ---

Abbreviations: ---, will not achieve goal of a 10% reduction by 2020; HP2020, Healthy People 2020.

Discussion
==========

Age-standardized death rates (population risk) began declining in the early 1990s and are predicted to continue to decline through 2020 for all cancer sites combined and for many of the leading cancers in both men and women. However, we predict that the total number of cancer deaths from 2007 to 2020 will increase more than 10% among men and black women and will begin to stabilize among white women, increasing only 4.4% during this period. Thus, while the overall risk of dying from cancer is declining, the impact of underlying demographic changes in the population will increase the burden of cancer on society and health care systems ([@R15]--[@R17]).

From 1975 to 2009, the observed number of cancer deaths increased among white Americans primarily because of an aging white population and among black Americans primarily because of a growing black population. Population aging has only recently begun to contribute to the increasing number of cancers deaths among black men. This shift can be explained by inequities in life expectancy. Compared with white Americans, life expectancy among black Americans in general and black men in particular remains lower because of higher death rates from heart disease, cancer, homicide, diabetes, and perinatal conditions ([@R18]). The demographic component underlying the increase in the number of cancer deaths is likely to continue into this century. Overall, the US population is expected to increase by 10% from 2010 to 2020; the largest increases are expected in minority populations and in the proportion of people older than 65 (13% to 16%) ([@R3]).

To help decrease the burden of cancer in the United States, HP2020 objectives called for a reduction in age-standardized death rates for all cancers combined, melanoma, and cancers of the female breast, cervix uteri, colon and rectum, lung and bronchus, oral cavity and pharynx, and prostate. In 2007, deaths from these cancers comprised the majority of cancer deaths ([@R2]). Many of these deaths could be prevented through reduced incidence of cancer, improved survival, or both. We predict that HP2020 target rates will be met first for prostate cancer in 2010 and lastly for all sites combined by 2015. We do not predict that melanoma cancer death rates will reach the HP2020 target rate by 2020. An examination of the most recent mortality data ([@R9]) shows that the HP2020 target for prostate cancer was met in 2010 and that the mortality rates for the other HP2020 targets declined as predicted with the exception of oral cavity and pharynx, which may be stabilizing.

An overarching goal of HP2020 is to improve the health of all population subgroups. These projections help inform the potential achievement of this goal. From 2007 to 2020, we predict a reduction of greater than 15% in death rates for colorectal cancer and a reduction of greater than 10% in death rates for cancers of the (female) breast, cervix, lung, oral cavity, and prostate, among white and black Americans. Despite this improvement, we expect that the total overall number of cancer deaths will increase in white men, black men, and black women and will begin to stabilize among white women. This trend reflects the impact of 2 leading cancers: we predict a modest 5.3% decline in the number of breast cancer deaths among white women, compared with a 15.3% increase among black women, and we predict that colorectal cancer deaths will decline by 10% among white women, stabilize among white men, and increase among black men and women.

The stabilization in deaths from lung cancer among men helps measure the success of primary prevention strategies aimed at reducing the incidence of cancer, particularly among highly fatal cancers. Incidence rates for lung cancer have been declining in parallel to a reduction in tobacco use ([@R19]). Among black women, the reduction in population risk is predicted to offset only partially the increase in lung cancer deaths attributable to demographic changes, and deaths are predicted to increase nearly 20% by 2020. Deaths from oral cancer are predicted to stabilize or decrease among women and black men during this period.

A reduction in the number of deaths from breast, cervical, and colorectal cancer among white women reflects the success of screening efforts and improved treatment. The reduction in age-standardized colorectal cancer death rates is consistent with a large reduction from screening and smaller reductions from risk factors and improved treatments ([@R20]). Access to quality health care, including earlier diagnosis and evidence-based treatments, has resulted in increased survival accompanied by reduced mortality for cancers of the colon and rectum and to a lesser extent, female breast and prostate ([@R21]).

Cancer projections can also alert researchers to the impact of changes in population risk before the full extent of the cancer burden manifests. This study identified several cancers in which increasing risk of death is exacerbating demographic trends, including cancers of corpus and uterus in black women, liver and intrahepatic bile duct cancer in both sexes and races, and thyroid cancer in women. Increasing cancer deaths, in part, reflect predicted increases in incidence rates of these cancers ([@R22]), possibly the result of a growing obesity epidemic (corpus and uterus cancer) ([@R23]), and an epidemic increase in hepatitis infections, particularly among those born from 1945 through 1965 (liver cancer) ([@R24]). The increase in deaths from thyroid cancer might be caused by unidentified risk factors operating at the population level and not the result of increased incidence associated with improved detection and access to care ([@R25],[@R26]).

Since 1975, melanoma incidence rates have increased among all age groups, whereas death rates have remained unchanged overall and increased in older age groups ([@R27]). Melanoma deaths are predicted to increase through 2020 because incidence rates and risk are predicted to continue to increase ([@R22]), and death rates and risk are predicted to fall short of the HP2020 target of a 10% reduction from 2007 to 2020. To address the increasing melanoma burden, HHS issued *The Surgeon General's Call to Action to Prevent Skin Cancer,* which includes strategies to reduce ultraviolet exposure from the sun and indoor tanning, thereby reducing melanoma incidence ([@R28]).

The estimates from our study are probably conservative, as the risk component in these models does not account for the potential for advances in primary prevention and treatment ([@R29]). Further reductions in cancer mortality, including melanoma, might yet be achievable if HP2020 objectives related to screening and access to health care are met ([@R30]).

This study used methods based on age-period cohort models that identify trends in younger birth cohorts and extrapolate these trends to future older cohorts ([@R12],[@R14]). Although these methods have been validated in studies using long-term incidence data and are based on the best available information, they are subject to many known limitations. First, the population projections underlying the predicted death rates are themselves forecasts of the population size and age composition based on assumptions regarding future births, deaths, and migration. As such, these projections have the potential to impact cancer death and death rate projections. Second, the change in the number of cases between time periods has been allocated into changes because of risk, age structure, and population size. This allocation is arbitrary because the 3 components mutually affect each other. For example, if the population size increases, the effect of higher death rates (the risk component) will be larger than if the population size does not change. In the analysis of past trends, the first year (1975) was used as the reference year, following the approach in Canada ([@R11]). In the analysis of future trends, the final year (2020) was preferred from a preventive prospective ([@R14]). The consequence of using the final year as a reference rate is that the change in the number of deaths because of the combined effect of risk, age structure, and population size is attributed to risk, not demographics. If a future reduction in the risk of death can be achieved, the number of deaths from the combined effect of risk and demographics will be reduced.
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